MISTIE KOCUREK: Open Payments
NPI 1629520184 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$557 in 24 payments from 15 companies in 2025. Trend: 2023 $258 · 2024 $342 · 2025 $557
Food & beverage: $557
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $239 |
| ABBVIE INC. | 2 | $48 |
| Corcept Therapeutics | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Exeltis, USA Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
Products named: Wegovy, Ozempic, Korlym, REXULTI, QULIPTA, XIFAXAN, Symbravo, GEMTESA.
Industry payments across TX — which companies pay providers there.
